33338256|t|The interaction of insoluble Amyloid-beta with soluble Amyloid-beta dimers decreases Amyloid-beta plaque numbers.
33338256|a|OBJECTIVES: The heterogeneity of Amyloid-beta (Abeta) plaque load in patients with Alzheimer's disease (AD) has puzzled neuropathology. Since brain Abeta plaque load does not correlate with cognitive decline, neurotoxic soluble Abeta oligomers have been championed as disease-causing agents in early AD. So far, investigating molecular interactions between soluble oligomeric Abeta and insoluble Abeta in vivo has been difficult because of the abundance of Abeta oligomer species and the kinetic equilibrium in which they coexist. Here, we investigated whether Abeta plaque heterogeneity relates to interactions of different Abeta conformers. MATERIALS AND METHODS: We took advantage of transgenic mice that generate exclusively Abeta dimers (tgDimer mice) but do not develop Abeta plaques or neuroinflammation during their lifetime, crossed them to the transgenic CRND8 mice that develop plaques after 90 days and measured Abeta plaque load using immunohistochemical and biochemical assays. Furthermore, we performed in vitro thioflavin T (ThT) aggregation assays titrating synthetic Abeta42 -S8C dimers into fibril-forming synthetic Abeta42 . RESULTS: We observed a lower number of Abeta plaques in the brain of double transgenic mice compared to tgCRND8 mice alone while the average plaque size remained unaltered. Corroborating these in vivo findings, synthetic Abeta-S8C dimers inhibited fibril formation of wild-type Abeta also in vitro, seen by an increased half-time in the ThT assay. CONCLUSIONS: Our study indicates that Abeta dimers directly interfere with Abeta fibril formation in vivo and in vitro. The variable interaction of Abeta dimers with insoluble Abeta seeds could thus contribute to the heterogeneity of Abeta plaque load in AD patients.
33338256	29	41	Amyloid-beta	Gene	351
33338256	55	67	Amyloid-beta	Gene	351
33338256	85	97	Amyloid-beta	Gene	351
33338256	147	159	Amyloid-beta	Gene	351
33338256	161	166	Abeta	Gene	351
33338256	183	191	patients	Species	9606
33338256	197	216	Alzheimer's disease	Disease	MESH:D000544
33338256	218	220	AD	Disease	MESH:D000544
33338256	262	267	Abeta	Gene	351
33338256	304	321	cognitive decline	Disease	MESH:D003072
33338256	323	333	neurotoxic	Disease	MESH:D020258
33338256	342	347	Abeta	Gene	351
33338256	414	416	AD	Disease	MESH:D000544
33338256	490	495	Abeta	Gene	351
33338256	510	515	Abeta	Gene	351
33338256	571	576	Abeta	Gene	351
33338256	675	680	Abeta	Gene	351
33338256	739	744	Abeta	Gene	351
33338256	812	816	mice	Species	10090
33338256	843	848	Abeta	Gene	11820
33338256	865	869	mice	Species	10090
33338256	890	895	Abeta	Gene	11820
33338256	907	924	neuroinflammation	Disease	MESH:D000090862
33338256	979	984	CRND8	CellLine	CVCL:4564
33338256	985	989	mice	Species	10090
33338256	1038	1043	Abeta	Gene	351
33338256	1141	1153	thioflavin T	Chemical	MESH:C009462
33338256	1155	1158	ThT	Chemical	MESH:C009462
33338256	1199	1206	Abeta42	Gene	351
33338256	1249	1256	Abeta42	Gene	351
33338256	1298	1303	Abeta	Gene	11820
33338256	1346	1350	mice	Species	10090
33338256	1371	1375	mice	Species	10090
33338256	1480	1485	Abeta	Gene	11820
33338256	1537	1542	Abeta	Gene	351
33338256	1596	1599	ThT	Chemical	MESH:C009462
33338256	1645	1650	Abeta	Gene	351
33338256	1682	1687	Abeta	Gene	351
33338256	1755	1760	Abeta	Gene	351
33338256	1783	1788	Abeta	Gene	351
33338256	1841	1846	Abeta	Gene	351
33338256	1862	1864	AD	Disease	MESH:D000544
33338256	1865	1873	patients	Species	9606
33338256	Association	MESH:D020258	351
33338256	Negative_Correlation	11820	351
33338256	Association	MESH:C009462	11820
33338256	Association	MESH:C009462	351
33338256	Association	MESH:D000544	351

